Li Ren

USPTO Granted Patents = 40 (Patent Applications = 17)

CIPO Patents = 8 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 32)

Average Co-Inventor Count = 9.2

ph-index = 6

Forward Citations = 127(Granted Patents)

Location History:

Superior, CO (US) (2022 - 2023)
Boulder, CO (US) (2012 - 2024)
Indianapolis, IN (US) (2024)

Company Filing History:

Eli Lilly and Company

patents

6. 1 out of 1

Enliven Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

40 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12351571 - Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases (2025-07-08),

2. 12303509 - Compounds for the treatment of BRAF-associated diseases and disorders (2025-05-20),

3. 12240846 - 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases (2025-03-04),

4. 12180207 - Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases (2024-12-31),

5. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

6. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

7. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

8. 11807649 - Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 (2023-11-07),

9. 11807638 - 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases (2023-11-07),

10. 11802127 - 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors (2023-10-31),

11. 11767321 - 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases (2023-09-26),

12. 11691973 - 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors (2023-07-04),

13. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

14. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders (2023-04-25),

15. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with an article about inventor Li Ren based on the provided details.

Title: Unveiling the Innovations of Li Ren in the Field of Medicine

Introduction:

Li Ren, a remarkable inventor based in Boulder, CO (US), has made significant contributions to the field of medicine with a total of 34 patents under her name. Her groundbreaking work revolves around developing compounds that act as inhibitors in the treatment of various diseases.

Latest Patents:

Li Ren's recent patents include two notable inventions:

1. Substituted pyrazolo[1,5-A]pyrazine compounds as RET kinase inhibitors - These compounds have shown promising results in inhibiting RET kinase and are beneficial in treating diseases mediated by this kinase.

2. Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 - These compounds are designed to inhibit ErbB2, including mutant forms harboring an Exon 20 mutation, with applications in the treatment of various cancers.

Career Highlights:

Li Ren has showcased her expertise while working in esteemed companies such as Array Biopharma Inc. and Genentech, Inc. Her innovative approach and dedication to developing novel solutions have been instrumental in advancing pharmaceutical research and development.

Collaborations:

Throughout her career, Li Ren has collaborated with notable professionals in the field, including coworkers David A Moreno and James F Blake. These collaborations have played a crucial role in fostering innovation and driving advancements in the medical industry.

Conclusion:

In conclusion, Li Ren's inventive spirit and commitment to scientific excellence have positioned her as a leading figure in the realm of medicine. Her patents and collaborations stand as a testament to her relentless pursuit of innovation and her significant impact on the healthcare landscape.dot

This text is generated by artificial intelligence and may not be accurate.